Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Completed
Trial end date:
2017-05-25
Target enrollment:
Participant gender:
Summary
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus
prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with
metastatic castration-resistant prostate cancer (CRPC).